Drug intelligence / Profile preview

SPVN50

Development stage: Unknown
Lead developer: SparingVision
Modality: Gene Therapies
Administration: Ophthalmic, Subretinal

Overview

SPVN50 is an investigational ocular gene editing therapy being developed by SparingVision in collaboration with Intellia Therapeutics. It is designed as a genome editing product for the treatment of inherited retinal diseases (IRDs), though the specific molecular target has not yet been disclosed. The therapy utilizes gene editing technology to address vision loss associated with these conditions. As of 2024, SPVN50 is in early-stage clinical development, including a phase I/II trial (PRODYGY) focused on safety and preliminary efficacy endpoints[1][2][3][4][7].

Beyond the preview

Go deeper on SPVN50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPVN50.

Explore the full profile